The NCI Leukemia Steering Committee (LKSC) was established in 2009. At monthly meetings, it addresses the design, prioritization, and evaluation of concepts for phase 2 and phase 3 clinical trials in adult leukemia. View the LKSC member roster as of November 7, 2025. The committee may periodically hold clinical trials planning meetings (CTPMs) to focus on specific clinical trial related topics.
Committee Highlights
The following are highlights from recent committee activities:
- Acute Myelogenous Leukemia (AML) Working Group
A series of teleconferences during 2014 and 2015 focused on the development of biomarker-driven trials in AML in older patients. This effort culminated in two in-person meetings in December 2015 and June 2016 to achieve consensus on the details of trial design. - Minimal Residual Disease in Adult Leukemia
Minimal residual disease (MRD) is the level or extent of leukemic cells remaining in the blood after initial treatment measured by either flow cytometry or DNA-based methods. It is an important prognostic tool but requires standardization for use in clinical trials. Two workshops were held in 2012 to address standardization.
Contact
For more information, contact NCI CCCT Program Director, Elena Schwartz, Ph.D., M.S., at elena.schwartz@nih.gov.